METAP2 and obesity due to melanocortin 4 receptor deficiency: Although the clinical development of beloranib was halted due to safety concerns, particularly thromboembolic events, its mechanism, targeting MetAP2 to influence lipid metabolism and energy expenditure, highlights its potential as a therapeutic candidate for obesity and related metabolic disorders.